Eric Matthews

Oncology

Post-ASCO 2025, Eric Matthews, chief business officer at Caris Life Sciences, discusses advancing the frontier of cancer diagnostics and treatment.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.